NEW YORK, July 15, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Prima Biomed Ltd (NASDAQ: PBMD), Oncothyreon
Inc. (NASDAQ: ONTY), Opko Health Inc. (NYSE: OPK), ImmunoCellular
Therapeutics Ltd (AMEX: IMUC), and Adaptimmune Therapeutics PLC
(NASDAQ: ADAP). Free research report on Prima Biomed can be
accessed at
https://www.EquityResearchInstitute.com/reports?keyword=PBMD On
Tuesday, July 14, 2015, the NASDAQ
Composite ended at 5,104.89, up 0.66%, the Dow Jones Industrial
Average advanced 0.42%, to finish the day at 18,053.58, and the
S&P 500 closed at 2,108.95, up 0.45%. The gains were broad
based as seven out of nine sectors ended the session in positive.
Register for your complimentary reports at the links given below.
Prima Biomed Ltd's stock surged 9.23%, to close the day at
$1.42. The stock recorded a trading
volume of 3.51 million shares, below its three months average
volume of 4.45 million shares. Over the previous three months and
since the start of this year, Prima Biomed Ltd's shares have
rallied 129.03% and 111.94%, respectively. However, the stock has
lost 27.55% in the last one month. The company's shares are trading
35.07% above their 200-day moving average. Additionally, Prima
Biomed Ltd has a Relative Strength Index (RSI) of 50.26. Sign up
and read the free notes on PBMD at:
https://www.EquityResearchInstitute.com/reports?keyword=PBMD
On Tuesday, shares in Oncothyreon Inc. recorded a trading volume
of 1.30 million shares, lower than their three months average
volume of 4.38 million shares. The stock ended the day 2.39% higher
at $3.85. Although Oncothyreon Inc.'s
stock has lost 0.77% in the last one month, it has surged 127.81%
in the previous three months and 102.63% on YTD basis. The company
is trading above its 50-day and 200-day moving averages by 20.30%
and 83.82%, respectively. Furthermore, shares of Oncothyreon Inc.
have an RSI of 61.99. The complimentary notes on ONTY can be
downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ONTY
Opko Health Inc.'s stock gained 1.03%, to close Tuesday's
session at $16.74. The stock recorded
a trading volume of 3.54 million shares, below its three months
average volume of 4.36 million shares. Over the last one month and
the previous three months, Opko Health Inc.'s shares have advanced
7.45% and 13.49%, respectively. Additionally, the stock has surged
67.57% since the start of this year. The company is trading 3.44%
and 34.57% above its 50-day and 200-day moving averages,
respectively. Furthermore, Opko Health Inc.'s stock has an RSI of
57.56. Register for free on Equity Research Institute and access
the latest research on OPK at:
https://www.EquityResearchInstitute.com/reports?keyword=OPK
ImmunoCellular Therapeutics Ltd's stock finished Tuesday's
session 0.31% higher at $0.49. A
total of 0.12 million shares were traded, which was below its three
months average volume of 0.52 million shares. Over the last one
month and the previous three months, ImmunoCellular Therapeutics
Ltd's shares have advanced 1.89% and 3.15%, respectively. However,
the stock has declined 33.56% on YTD basis. The company's shares
are trading above their 50-day moving average by 0.79%.
ImmunoCellular Therapeutics Ltd's stock has an RSI of 50.11. The
complete research on IMUC is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=IMUC
On Tuesday, shares in Adaptimmune Therapeutics PLC ended the
session 6.49% higher at $17.06. The
stock reported a trading volume of 0.47 million shares, close to
its three months average volume of 0.52 million shares. Adaptimmune
Therapeutics PLC's shares have lost 11.56% in the last one month.
However, the stock has advanced 6.62% on YTD basis. The
company is trading 0.27% below its 50-day and 200-day moving
averages, each. Moreover, shares of Adaptimmune Therapeutics PLC
have an RSI of 46.86. Free in-depth research on ADAP is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=ADAP
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com